The impact of cytomegalovirus infection ≥1 year after primary renal transplantation

Clinical Transplantation

Volumn 24, Issue 4, 2010, Pages 572-577

  Browne, Barry J ^a   Young, Jo Anne ^b   Dunn, Ty B ^b   Matas, Arthur J ^b  

^a Transplant Services   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Cytomegalovirus; Infection; Late; Post transplant; Renal transplant

Indexed keywords

ACICLOVIR; ANTIMETABOLITE; CALCINEURIN INHIBITOR; GANCICLOVIR; PREDNISONE; STEROID; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; AGED; ARTICLE; CHEMOPROPHYLAXIS; CHILD; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFECTION RISK; KIDNEY DONOR; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77955751486     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2010.01208.x     Document Type: Article

References (20)

1. Reischig T, Jindra P, Hes O, Švecová M, Klabocha J, Třeška V. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant 2008, 8:69.
2. Linnemann CC, Dunn CR, First MR, Alvira M, Schiff GM. Late onset of fatal cytomegalovirus infection after renal transplantation. Primary or reactivation infection? Arch Intern Med 1978, 138:1247.
3. Barnett PS, Meyers AM, Schoub BD, Johnson S, Botha JR. Acyclovir in cytomegalovirus infection 3 1/2 years after renal transplantation. An unusual case and dramatic response. S Afr Med J 1984, 66:635.
4. Boehler A, Schaffner A, Salomon F, Keusch G. Cytomegalovirus disease of late onset following renal transplantation: a potentially fatal entity. Scand J Infect Dis 1994, 26:369.
5. Becker BN, Becker YT, Leverson GE, Simmons WD, Sollinger HW, Pirsch JD. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation. Am J Kidney Dis 2002, 39:1088.
6. Zandberg M, de Maar EF, Hofker HS, Homan van der Heide JJ, Rosati S, van Son WJ. Initial cytomegalovirus prophylaxis with ganciclovir: no guarantee for prevention of late serious manifestations of CMV after solid organ transplantation. Neth J Med 2005, 63:408.
7. Limaye AP, Bakthavatsalam R, Kim HW. Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis. Transplantation 2004, 78:1390.
8. Shibolet O, Ilan Y, Kalish Y. Late cytomegalovirus disease following liver transplantation. Transpl Int 2003, 16:861.
9. Slifkin M, Tempesti P, Poutsiaka DD, Snydman DR. Late and atypical cytomegalovirus disease in solid-organ transplant recipients. Clin Infect Dis 2001, 33:E62.
10. Jochimsen F, Westhoff T, Engelmann E, Schafer JH, Offermann G, Zidek W. Late-onset cytomegalovirus reactivation in critically ill renal transplant patients. Transplantation 2003, 76:430.
11. Razonable RR, Rivero A, Rodriguez A. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 2001, 184:1461.
12. Singh N, Zeevi A, Gayowski T, Marino IR. Late onset cytomegalovirus disease in liver transplant recipients: de novo reactivation in recurrent hepatitis C virus hepatitis. Transpl Int 1998, 11:308.
13. Limaye AP, Bakthavatsalam R, Kim HW. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 2006, 81:1645.
14. Boobes Y, Al Hakim M, Dastoor H, Bernieh B, Abdulkhalik S. Late cytomegalovirus disease with atypical presentation in renal transplant patients: case reports. Transplant Proc 2004, 36:1841.
15. Arthurs SK, Eid AJ, Pedersen RA. Delayed-onset primary cytomegalovirus disease after liver transplantation. Liver Transpl 2007, 13:1703.
16. Arthurs SK, Eid AJ, Pedersen RA. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008, 46:840.
17. Matas AJ, Sutherland DE, Najarian JS. Evolution of immunosuppression at the University of Minnesota. Transplant Proc 2004, 36(Suppl. 1):64S.
18. Matas AJ, Ramcharan T, Paraskevas S. Rapid discontinuation of steroids in living donor kidney transplantation. A pilot study. Am J Transplant 2001, 1:278.
19. Balfour HH, Chace BA, Stapleton JT, Simmons RL, Fryd DS. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989, 320:1381.
20. Fishman JA, Emery V, Freeman R. Cytomegalovirus in transplantation - challenging the status quo. Clin Transplant 2007, 21:149.